The role of the complement anaphylatoxins in the recruitment of eosinophils

International Immunopharmacology

Volumn 7, Issue 14, 2007, Pages 1909-1923

  DiScipio, Richard G ^a   Schraufstatter, Ingrid U ^a  

^a LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Anaphylatoxins; C3a; C5a; Complement; Eosinophils

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; GELATINASE B; HISTAMINE; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE C4; NITRIC OXIDE; OXIDIZING AGENT; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC REACTION; BASOPHIL; BLOOD VESSEL PERMEABILITY; CHEMOTAXIS; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; EOSINOPHIL; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BASOPHILS; CELL ADHESION; CELL COMMUNICATION; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C5A; EOSINOPHILIA; EOSINOPHILS; HUMANS; INFLAMMATION; MAST CELLS; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTORS, COMPLEMENT; SELECTINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 36248971186     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.07.006     Document Type: Review

References (171)

1. Sehmi R., and Denburg J.A. Differentiation of human eosinophils. Role in allergic inflammation. Chem Immunol 76 (2000) 29-44
2. Walle A.J., and Parwaresch M.R. Estimation of effective eosinopoiesis and bone marrow eosinophil reserve capacity in normal man. Cell Tissue Kinet 65 (1979) 1269-1274
3. Foster P.S., Mould A.W., Yang M., Mackenzie J., Mattes J., Hogan S.P., et al. Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev 179 (2001) 173-181
4. Rothernberg M.E., Mishra A., Brandt E.B., and Hogan S.P. Gastrointestinal eosinophils. Immunol Rev 179 (2001) 139-155
5. Gouon-Evans V., and Pollard J.W. Eotaxin is required from eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology 142 (2001) 4515-4521
6. Gouon-Evans V., Rothernberg M.E., and Pollard J.W. Postnatal mammary gland development requires macrophages and eosinophils. Development 127 (2000) 2269-2282
7. Rothenberg M.D., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
8. Gonlugur U., and Efeoglu T. Vascular adhesion and transendothelial migration of eosinophil leukocytes. Cell Tissue Res 318 (2004) 473-482
9. Munitz A., and Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy 59 (2004) 268-275
10. Dvorak A.M., and Weller P.F. Ultrastructural analysis of human eosinophils. Clin Immunol (2000) 1-28
11. Swaminathan G.J., Weaver A.J., Loegering D.A., Checkel J.L., Leonidas D.D., Gleich G.J., et al. Crystal structure of the Eosinophil major basic protein at 1.8 Å: an atypical lectin with a paradigm shift in specificity. J Biol Chem (2001) 26197-26203
12. Hamann K.J., Barker R.L., Loegering D.A., Pease L.R., and Gleich G.J. Sequence of human eosinophil derived neurotoxin cDNA: identity of deduced amino acid sequence with human nonsecretory ribonucleases. Gene 83 (1989) 161-167
13. Rosenberg H.F., Ackerman S.J., and Tenen D.G. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 170 (1989) 163-176
14. Ten R.M., Pease L.R., McKean D.J., Bell M.P., and Gleich G.J. Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med 169 (1989) 1757-1769
15. Butterworth A.E. Cell-mediated damage to helminths. Adv Parasitol 23 (1984) 144-235
16. Ramos A.L., DiScipio R.G., and Ferreira A.M. Eosinophil cationic protein damages protoscoleces in vitro and is present in the hydatid cyst. Parasite Immunol 28 (2006) 347-355
17. Hamann K.J., Gleich G.J., Checkel J.L., Loegering D.A., McCall J.W., and Barker R.L. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol 144 (1990) 3166-3173
18. Hamann K.J., Barker R.L., Loegering D.A., and Gleich G.J. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol 73 (1987) 523-529
19. Yazdanbakhsh M., Tai P.C., Spry C.J., Gleich G.J., and Roos D. Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni. J Immunol 138 (1987) 3443-3447
20. Hastie A.T., Loegering D.A., Gleich G.J., and Kueppers F. The effect of purified human eosinophil major basic protein on mammalian ciliary activity. Am Rev Respir Dis 135 (1987) 848-853
21. Butterworth A.E., and Thorne K.J.I. Eosinophils and parasitic diseases. In: Smith H., and Cook B.M. (Eds). Immunopharmacology of eosinophils (1993), Academic Press, San Diego 115-150
22. Klion A.D., and Nutman T.B. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113 (2004) 30-37
23. Allen J.N., and Davis W.B. Eosinophilic lung diseases. Am J Respir Crit Care Med 150 (1994) 1423-1438
24. Hogan S.P., and Rothenberg M.E. Eosinophil function in eosinophil associated gastrointestinal disorders. Curr Allergy Asthma Rep 6 (2006) 65-71
25. Rothenberg M.E., Mishra A., Brandt E.B., and Hogan S.P. Gastrointestinal eosinophils in health and disease. Adv Immunol 78 (2001) 291-328
26. Persson T., Andersson P., Bodelsson M., Laurell M., Malm J., and Egesten A. Bactericidal activity of human eosinophilic granulocytes against Escherichia coli. Infect Immun 69 (2001) 3591-3596
27. Tepper R.I., Coffman R.L., and Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257 (1992) 548-551
28. Jong E.C., and Klebanoff S.J. Eosinophil mediated mammalian tumor cell cytotoxicity: role of peroxidases system. J Immunol 124 (1980) 1949-1953
29. Moqbel R., Levi-Schaffer F., and Kay A.B. Cytokine generation by eosinophils. J Allergy Clin Immunol 94 (1994) 1183-1188
30. Lacy P., and Moqbel R. Eosinophil cytokines. Chem Immunol 76 (2000) 134-155
31. Del Pozo V., De Andres B., Martin E., Cardaba B., Fernandez J.C., Gallardo S., et al. Eosinophil as antigen presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol 22 (1992) 1919-1925
32. Shi H.Z. Eosinophils function as antigen presenting cells. J Leukoc Biol 76 (2004) 520-527
33. Ponath P.D., Qin S., Ringler D.J., Clark-Lewis I., Wang J., Kassam N., et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 97 (1996) 604-612
34. Elsner J., Petering H., Kluthe C., Kimmig D., Smolarski R., Ponath P., et al. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertusssis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 28 (1998) 2152-2158
35. Alam R., Stafford S., Forsythe P., Harrison R., Faubion D., Lett-Brown M.A., et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 150 (1993) 3442-3448
36. Noso N., Proost P., Van Damme J., and Schroder J.M. Human monocyte chemotactic proteins 2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. Biochem Biophys Res Commun 200 (1994) 1470-1476
37. Shahabuddin S., Ponath P., and Schleimer R.P. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial activating cytokines, and C-C cytokines. J Immunol 164 (2000) 3847-3854
38. Morita E., Schroder J.-M., and Cristophers E. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins. Scand J Immunol 29 (1989) 709-716
39. Wardlaw A.J., Moqbel R., Cromwell O., and Kay A.B. Platelet activating factor: a potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78 (1986) 1701-1706
40. Daffern P.J., Pfeifer P.H., Ember J.A., and Hugli T.E. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181 (1995) 2119-2127
41. DiScipio R.G., Daffern P.J., Jagels M.A., Broide D.H., and Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162 (1999) 1127-1136
42. Hugli T.E. Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem 250 (1975) 8293-8301
43. Fernandez H., and Hugli T.E. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. J Biol Chem 253 (1978) 6955-6962
44. Hugli T.E. Biochemistry and biology of anaphylatoxins. Complement 3 (1986) 111-127
45. Hugli T.E. Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol 153 (1990) 181-208
46. Huber R., Scholze H., Paques E.P., and Deisenhofer J. Crystal structure analysis and molecular model of human C3a anaphylatoxin. Hoppe Seylers Z Physiol Chem 361 (1980) 1389-1399
47. Zhang X., Boyar W., Toth M.J., Wennogle L., and Gonnella N.C. Structural definition of the C5a C terminus by two dimensional nuclear magnetic resonance spectroscopy. Proteins 28 (1997) 261-267
48. Fernandez H.N., Henson P.M., Otani A., and Hugli T.E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J Immunol 120 (1978) 109-115
49. Bokisch V.A., and Muller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 49 (1970) 2427-2436
50. Guo R.F., and Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol 23 (2005) 821-852
51. Gerard N.P., and Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 349 (1991) 614-617
52. Roglic A., Prossnitz R.R., Cavanagh S.L., Pan Z., Zou A., and Ye R.D. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim Biophys Acta 1305 (1996) 39-43
53. Ames R.S., Li Y., Sarau H.M., Nuthulaganti P., Foley J.J., and Ellis C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 271 (1996) 20231-20234
54. Teixeira M., Giembycz M.A., Lindsay M.A., and Hellewell P.G. Pertussis toxin shows distinct early signalling events in platelet activating factor, leukotriene B4, and C5a induced eosinophil homotypic aggregation in vitro and recruitment in vivo. Blood 89 (1997) 4566-4573
55. + 2 influx in neutrophils via a pertussis-toxin sensitive G protein. Eur J Biochem 217 (1993) 289-294
56. Coffer P.J., Schweizer R.C., Dubois G.R., Maikoe T., Lammers J.W., and Koenderman L. Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and the T-helper 2 derived cytokines interleukin-4 and interleukin-5. Blood 91 (1998) 2547-2557
57. Hakansson L., and Venge P. Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5. APMIS 102 (1994) 308-316
58. Moser R., Fehr J., Olgiati L., and Bruijnzeel P.L. Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers. Blood 79 (1992) 2937-2945
59. Okada S., Kita H., George T.J., Gleich G.J., and Leiferman K.M. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. Am J Respir Cell Mol Biol 16 (1997) 455-463
60. Tedder T.F., Steeber D.A., Chen A., and Engel P. The selectins: vascular adhesion molecules. FASEB J 9 (1995) 866-873
61. Kitayama J., Fuhlbrigge R.C., Puri K.D., and Springer T.A. P-selectin, L-selectin, and α4 integrin have distinct roles in eosinophil tethering and arrest on vascular endothelial cells under physiological flow conditions. J Immunol 159 (1997) 3929-3939
62. Alon R., Kassner P.D., Carr M.W., Finger E.B., Hemler M.E., Springer T.A., et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 128 (1995) 1243-1253
63. Patel K.D., and McEver R.P. Comparison of tethering and rolling of eosinophils and neutrophils through selectins and P-selectin glycoprotein ligand-1. J Immunol 159 (1997) 4555-4565
64. Knol E.F., Tackey F., Tedder T.F., Klunk D.A., Bickel C.A., Sterbindky S.A., et al. Comparison of human eosinophil and neutrophil adhesion to endothelial cells under nonstatic conditions. Role of L-selectin. J Immunol 153 (1994) 2161-2167
65. Bochner B.S., Sterbinsky S.A., Bickel C.A., Werfel S., Wein M., and Newman W. Differences between human eosinophils and neutrophils in the function and expression of sialic acid containing counterligands for E-selectin. J Immunol 152 (1994) 774-782
66. Sriramarao P., Norton C.R., Borgstrom P., DiScipio R.G., Wolitzky B.A., and Broide D.H. E-Selectin preferentially supports neutrophil but not eosinophil rolling under conditions of flow in vitro and in vivo. J Immunol 157 (1996) 4672-4680
67. Suzuki A., Andrew D.P., Gonzalo J.-A., Fukumoto M., Spellberg J., Hashiyama M., et al. CD34 deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Blood 87 (1996) 3550-3562
68. Symon F.A., Lawrence M.B., Williamson M.L., Walsh G.M., Watson S.R., and Wardlaw A.J. Functional and structural characterization of eosinophil P-selectin ligand. J Immunol 157 (1996) 1711-1719
69. Foreman K.E., Vaporciyan A.A., Bonish B.K., Jones M.L., Johnson K.J., Glovsky M.M., et al. C5a induced expression of P-selectin in endothelial cells. J Clin Invest 94 (1994) 1147-1155
70. Mulligan M.S., Schmid E., Till G.O., Hugli T.E., Friedl H.P., Roth R.A., et al. C5a dependent up regulation in vivo of lung vascular P-selectin. J Immunol 158 (1997) 1857-1861
71. Woltmann G., McNulty C.A., Dewson G., Symon F.A., and Wardlaw A.J. Interleukin-13 induces PSGL-1/P selectin dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow. Blood 95 (2000) 3146-3152
72. Wickham T.J. Adhesion molecules: integrins. In: Crystal R.G., West J.B., Barnes P.J., Weibel E.R., Crystal R.G., West J.B., Barnes P.J., and Weibel E.R. (Eds). The Lung: Scientific Foundations (1997), Lippincott-Raven, Philadelphia 201-214
73. Elices M.J., Osborn L., Takada Y., Crouse C., Luhowskyj S., Hemler M.E., et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60 (1990) 577-584
74. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine induce endothelial protein that binds to lymphocytes. Cell 59 (1989) 1203-1211
75. Sano H., Nakagawa N., Nakajima H., Yoshida S., and Iwamoto I. Role of vascular cell adhesion molecule-1 and platelet-activating factor in selective eosinophil migration across vascular endothelial cells. Int Arch Allergy Immunol 107 (1995) 533-540
76. Schleimer R.P., Sterbinsky S.A., Kaiser J., Bickel C.A., Klunk D.A., Tomioka K., et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 148 (1992) 1086-1092
77. Bochner B.S., Klunk D.A., Sterbinsky S.A., Coffman R.L., and Schleimer R.P. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 154 (1995) 799-803
78. Ebisawa M., Liu M.C., Yamada T., Kato M., Lichtenstein L.M., Bochner B.S., et al. Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil active cytokines. J Immunol 152 (1994) 4590-4596
79. Jagels M.A., Daffern P.J., and Hugli T.E. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 46 (2000) 209-222
80. Ebisawa M., Bochner B.S., Georas S.N., and Schleimer R.P. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1β induced transendothelial migration. J Immunol 149 (1992) 4021-4028
81. Shakoory B., Fitzgerald S.M., Lee S.A., Chi D.S., and Krishnaswamy G. The role of human mast cell derived cytokines in eosinophil biology. J Interferon Cytokine Res 24 (2004) 271-281
82. Hartmann K., Henz B.M., Kruger-Krasagakes S., Kohl J., Burger R., Guhl S., et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89 (1997) 2863-2870
83. Johnson A.R., Hugli T.E., and Muller-Eberhard H.J. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 28 (1975) 1067
84. el-Lati S.G., Dahinden C.A., and Church M.K. Complement peptides C3a and C5a induced mediator release from dissociated human skin mast cells. J Invest Dermatol 102 (1994) 803-806
85. Piliponsky A.M., Pickholtz D., Gleich G.J., and Levi-Schaffer F. Eosinophils activate mast cells to release histamine. Int Arch Allergy Immunol 118 (1999) 202-203
86. Lett-Brown M.A., Boetcher D.A., and Leonard E.J. Chemotactic responses of normal human basophils to C5a and to lymphocyte-derived chemotactic factor. J Immunol 117 (1976) 246-252
87. Eglite S., Pluss K., and Dahinden C.A. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J Immunol 165 (2000) 2183-2189
88. Kurimoto Y., De Weck A.L., and Dahinden C.A. Interleukin-3 dependent mediator release in basophils triggered by C5a. J Exp Med 170 (1989) 467-479
89. Bischoff S.C., Brunner T., De Weck A.L., and Dahinden C.A. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 172 (1990) 1577-1582
90. Schulman E.S., Post T.J., Henson P.M., and Giclas P.C. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 81 (1988) 918-923
91. Dahinden C.A., Kurimoto J., Baggiolini M., Dewald B., and Walz A. Histamine and sulfidoleukotriene release from human basophils: different effects of antigen, anti-IgE, C5a, f-Met-Leu-Phe and the novel neutrophil activating peptide NAF. Int Arch Allergy Appl Immunol 90 (1989) 113-118
92. Glovsky M.M., Hugli T.E., Ishizaka T., Lichtenstein M., and Erickson B.W. Anaphylatoxin induced histamine release with human leukocytes. J Clin Invest 64 (1979) 804-811
93. Kubes P., and Kanwar S. Histamine induces leukocyte rolling in post-capillary venules. A P-selectin mediated event. J Immunol 152 (1994) 3570-3577
94. Burgi B., Brunner T., and Dahinden C.A. The degradation product of the C5a anaphylatoxin C5adesarg retains basophil-activating properties. Eur J Immunol 24 (1994) 1583-1589
95. Kita H., Ohnishi T., Okubo Y., Weiler D., Abrams J.S., and Gleich G.J. Granulocyte-macrophage colony stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 174 (1991) 743-748
96. Solomon A., Aloe L., Pe J., Frucht-Pery J., Bonini S., and Levi-Schaffer F. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 102 (1998) 454-460
97. Kobayashi H., Gleich G.J., Butterfield J.H., and Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 99 (2002) 2214-2220
98. Soruri A., Riggert J., Schlott T., Kiafard Z., Dettmer C., and Zwirner J. Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-alpha and prostaglandin E2 dependent mechanisms. J Immunol 171 (2003) 2631-2636
99. Morelli A., Larregina A., Chuluyan I., Kolkowski E., and Fainboim L. Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology 89 (1996) 126-134
100. Sozzani S., Sallusto F., Luini W., Zhou D., Piemonti L., Allavena P., et al. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 155 (1995) 3292-3295
101. Gutzmer R., Lisewski M., Zwirner J., Mommert S., Diesel C., Wittmann M., et al. Human monocyte derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 111 (2004) 435-443
102. Okusawa S., Dinarello C.A., Yancey K.B., Endres S., Lawley T.J., Frank M.M., et al. C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. J Immunol 139 (1987) 2635-2640
103. Okusawa S., Yancey K.B., Van der Meer J.W., Endres S., Lonnemann G., Hefter K., et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 168 (1988) 443-448
104. Cavaillon J.M., Fitting C., and Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide stimulated monocytes and macrophages. Eur J Immunol 20 (1990) 253-257
105. Wittmann M., Zwirner J., Larsson V.A., Begemann G., Kapp A., Gotze O., et al. C5a suppresses the production of IL-12 by IFN-gamma primed and lipopolysaccharide challenged human monocytes. J Immunol 162 (1999) 6763-6769
106. Braun M.C., Lahey E., and Kelsall B.L. Selective suppression of IL-12 production by chemoattractants. J Immunol 164 (2000) 3009-3017
107. Neurath M.F., Finotto S., and Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8 (2002) 567-573
108. Hawlisch H., Wills-Karp M., Karp C.L., and Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 41 (2004) 123-131
109. Drouin S.M., Corry D.B., Hollman T.J., Kildsgaard J., and Wetsel R.A. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 169 (2002) 5926-5933
110. Karp C.L., Grupe A., Schadt E., Keane-Moore M., Cuomo P.J., Kohl J., et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 1 (2000) 190-192
111. Kohl J., Baelder R., Lewkowich I.P., Pandey M.K., Hawlisch H., Wang L., et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 116 (2006) 783-796
112. Albrecht E.A., Chinnaiyan A.M., Varambally S., Kumar-Sinha C., Barrette T.R., Sarma J.V., et al. C5a induced gene expression in human umbilical vein endothelial cells. Am J Path 164 (2004) 849-859
113. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., and Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production human umbilical vein endothelial cells. FASEB J 17 (2003) 1003-1014
114. Lub M., van Kooyk Y., and Figdor C.G. Ins and outs of LFA-1. Immunol Today 16 (1995) 479-483
115. Simmons D., Makgoba M.W., and Seed B. ICAM, an adhesion ligand for LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 331 (1988) 624-627
116. Staunton D.E., Dustin M.L., and Springer T.A. Functional cloning of a ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339 (1989) 61-64
117. Diamond M.S., Staunton D.E., de Fougerolles A.R., Stacker S.A., Garcia-Aguilar J., Hibbs M.L., et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 111 (1990) 3129-3139
118. Walsh G.M., Mermod J.-J., Hartnell A., Kay A.B., and Wardlaw A.J. Human eosinophil but not neutrophil adherence to IL-1 stimulated human umbilical vein endothelial cells is α4β1 (very late antigen-4) dependent. J Immunol 146 (1991) 3419-3423
119. Walsh G.M., Symon F.A., Lazarovits A.L., and Wardlaw A.J. Integrin alpha 4 beta 7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology 89 (1996) 112-119
120. Elsner J., Oppermann M.L., Czech W., Dobos G., Schopf E., Norgauer J., et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24 (1994) 518-522
121. Zeck-Kapp G., Kroegel C., Riede U.N., and Kapp A. Mechanisms of human eosinophil activation by complement protein C5a and platelet activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy 50 (1995) 34-47
122. Patel K.D., Zimmerman G.A., Prescott S.M., McEver R.P., and McIntyre T.M. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 112 (1991) 749-759
123. Lo S.K., Janakidevi K., Lai L., and Malik A. Hydrogen peroxide induced increase in endothelial adhesiveness is dependent on ICAM-1 activation. Am J Physiol 264 (1993) L406-L412
124. Wang J.G., Mahmud S.A., Nguyen J., and Slungaard A. Thiocyanate dependent induction of endothelial cell molecule expression by phagocyte peroxidases: a novel HOSCN specific oxidant mechanism to amplify inflammation. Immunology 177 (2006) 8714-8722
125. Nagata M., Yamamoto H., Shibasashi M., Sakamoto Y., and Matsuo H. Hydrogen peroxide augments eosinophil adhesion via beta2 integrin. Immunology 101 (2000) 412-418
126. Guzik T.J., Korbut R., and Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54 (2003) 469-487
127. Del Pozo V., De Arruda-Chaves E., De Andres B., Cardaba B., Lopez-Farre A., Gallardo S., et al. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J Immunol 158 (1997) 859-864
128. Lowenstein C.J., and Padalko E. iNOS (NOS2) at a glance. J Cell Sci 117 Pt 14 (2004) 2865-2867
129. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
130. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297 (2002) 1186-1190
131. Discipio R.G., Schraufstatter I.U., Sikora L., Zuraw B.L., and Sriramarao P. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int Immunopharmacol 6 (2006) 1109-1118
132. Denis M. Human monocytes/macrophages: NO or no NO. J Leukoc Biol 55 (1994) 682-684
133. Wu W., Chen Y., and Hazen S.L. Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 274 (1999) 25933-25944
134. MacPherson J.C., Comhair S.A., Erzurum S.C., Klein D.F., Lipscomb M.F., Karvuru M.S., et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 166 (2001) 5763-5772
135. Bjork J., Hugli T.E., and Smedegard G. Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134 (1985) 1115-1119
136. Weber C., Katayama J., and Springer T.A. Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci U S A 93 (1996) 10939-10944
137. Tachimoto H., Burdick M.M., Hudson S.A., Kikuchi M., Konstantopoulos K., and Bochner B.S. CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 in vitro. J Immunol 165 (2000) 2748-2754
138. Yamamoto H., and Nagata M. Regulatory mechanisms of eosinophil adhesion to and transmigration across endothelial cells by alpha4 and beta2 integrins. Int Arch Allergy Immunol 120 Supplement 1 (1999) 24-26
139. Schraufstatter I.U., Trieu K., Sikora L., Sriramarao P., and DiScipio R.G. Complement C3a and C5a induce different signal transduction cascades in endothelial cells. J Immunol 169 (2002) 2102-2110
140. Newman P.J., Berndt M.C., Gorski J., White G.C., Lyman S., Paddock C., et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247 (1990) 1219-1222
141. Muller W.A., Weigl S.A., Deng X., and Philips D.M. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178 (1993) 449-460
142. Miller M., Sung K.-L.P., Muller W.A., Cho J.Y., Castaneda D., Roman M., et al. Eosinophil tissue recruitment to sites of allergic inflammation in the lung is platelet endothelial cell adhesion molecule independent. J Immunol 167 (2001) 2292-2297
143. Hindmarsh E.J., and Marks R.M. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 160 (1998) 6128-6136
144. Sim R.B., Twose T.M., Paterson D.S., and Sim E. The covalent binding reaction of complement component C3. Biochem J 193 (1981) 115-127
145. Tack B.F., Harrison R.A., Janatova J., and Thomas M.L. Evidence for presence of an internal thiol ester bond in the third component of human complement. Proc Natl Acad Sci U S A 77 (1980) 5764-5768
146. Fischer E., Capron M., Prin L., Kusnierz J.P., and Kazatchkine M.D. Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol 97 (1986) 297-306
147. Klickstein L.B., Bartow T.J., Miletic V., Rabson L.D., Smith J.A., and Fearon D.T. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168 (1988) 1699-1717
148. Sim E., Wood A.B., Hsiung L.-M., and Sim R.B. Pattern of degradation of human complement fragment C3b. FEBS Lett 132 (1981) 55-60
149. Whaley K., and Ruddy S. Modulation of the alternative complement pathway by β1H globulin. J Exp Med 144 (1976) 1147-1163
150. Myones B.L., Dalzell J.G., Hogg N., and Ross G.D. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest 82 (1988) 640-651
151. Diamond M.S., Alon R., Parkas C.A., Quinn M.T., and Springer T.A. Heparin is an adhesive ligand for leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 130 (1995) 1473-1482
152. Iozzo R.V., Cohen I.R., Grassel S., and Murdoch A.D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302 (1994) 625-639
153. Neeley S.P., Hamann K.J., Dowling T.L., McAllister K.T., White S.R., and Leff A.R. Augmentation of stimulated eosinophil degranulation by VLA-4 (CD49d)-mediated adhesion to fibronectin. Am J Respir Cell Mol Biol 11 (1994) 206-213
154. Georas S.N., McIntyre B.W., Ebisawa M., Bednarczyk J.L., Sterbinsky S.A., Schleimer R.P., et al. Expression of a functional laminin receptor (α6β1, very late activation antigen-6) on human eosinophils. Blood 82 (1993) 2872-2879
155. Okada S., Kita H., George T.J., Gleich G.J., and Leiferman K.M. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol 17 (1997) 519-528
156. Fujisawa T., Kato Y., Terada A., Iguchi K., and Kamiya H. Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol 120 Suppl. 1 (1999) 65-69
157. Birkedal-Hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal-Hanser B., DeCarlo A., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 (1993) 197-250
158. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87 (1990) 5578-5582
159. Shipley J.M., Doyle G.A., Fliszar C.J., Ye Q.Z., Johnson L.L., Shapiro S.D., et al. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinase. Role of the fibronectin type II-like repeats. J Biol Chem 271 (1996) 4335-4341
160. Collier I.E., Krasnov P.A., Strongin A.Y., Birkedal-Hansen H., and Goldberg G.I. Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen binding domain from human 92 kDa type IV collagenase. J Biol Chem 267 (1992) 6776-6781
161. Takafuji S., Ishida A., Miyakuni Y., and Nakagawa T. Matrix metalloproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol 13 (2003) 50-55
162. Ohno I., Ohtani H., Nitta Y., Suzuki J., Hoshi H., Honma M., et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 16 (1997) 212-219
163. Levi-Schaffer F., Garbuzenko E., Rubin A., Reich R., Pickholz D., Gillery P., et al. Human eosinophils regulate human lung and skin derived fibroblast properties in vitro: a role for transforming growth factor β (TGF-β). Proc Natl Acad Sci U S A 96 (1999) 9660-9665
164. Horiuchi T., and Weller P. Expression of vascular endothelial growth factor by human eosinophil: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 17 (1997) 70-77
165. Senior R.M., Griffin G.L., Perez H.D., and Webster R.O. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts. J Immunol 141 (1988) 3570-3574
166. Marc M.M., Korosec P., Kosnik M., Kern I., Flezar M., Suskovic S., et al. Complement factors C3a, C4a, and C5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 31 (2004) 216-219
167. Ali H., and Panettieri R.A. Anaphylatoxin C3a receptors in asthma. Respir Res 6 (2005) 6-19
168. Krug N., Tschernig T., Erpenbeck V.J., Hohlfeld J.M., and Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 164 (2001) 1841-1843
169. Fregonese L., Swan F.J., Van Schadewijk A., Dolhnikoff M.D., Daha M.R., Santos M.A., et al. Expression of the anaphylatoxIn receptors C3aR and C5aR is increased in fatal asthma. J Allergy Clin Immunol 115 (2005) 1148-1154
170. Sumichika H. C5a receptor antagonists for the treatment of inflammation. Curr Opin Investig Drugs 5 (2004) 505-510
171. Allegretti M., Moriconi A., Beccari A.R., DiBitodo R., Bizzarri C., Bertini R., et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem 12 (2005) 217-236